CTNM

Contineum Therapeutics

• Reuters·2d ago

  Contineum CSO Daniel S. Lorrain disposes of 4,170 shares for $56,025

• Simply Wall St·03/27 10:10

  Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth

• Reuters·03/13 20:05

  Contineum Therapeutics grants 51,000-share inducement stock option under 2026 employment plan

• Reuters·03/13 20:05

  CONTINEUM THERAPEUTICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

• TipRanks·03/10 10:45

  Morgan Stanley Reaffirms Their Hold Rating on Contineum Therapeutics, Inc. Class A (CTNM)

• TipRanks·03/09 10:30

  Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS)

• Dow Jones·03/06 12:52

  Contineum Therapeutics Is Maintained at Outperform by Baird

• Dow Jones·03/06 12:52

  Contineum Therapeutics Price Target Raised to $20.00/Share From $14.00 by Baird

• Benzinga·03/06 12:41

  Baird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20

• TipRanks·03/06 11:56

  RBC Capital Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)

• TipRanks·03/06 11:56

  Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

• TipRanks·03/06 11:41

  Contineum price target raised to $20 from $14 at Baird

• TipRanks·03/06 11:20

  Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP) and Contineum Therapeutics, Inc. Class A (CTNM)

• Reuters·03/05 21:48

  CONTINEUM THERAPEUTICS INC - MAY OFFER CLASS A COMMON STOCK UP TO $100 MLN THROUGH LEERINK PARTNERS - SEC FILING

• Dow Jones·03/05 21:40

  *Contineum Therapeutics 2Q Loss/Shr 49c >CTNM